Pucotenlimab not checked

Lepu Biopharma Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 2 trial completes
Trials
4 active
4 in total · 1 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“MRG003 will be administrated as specified in the protocol. Pucotenlimab will be administrated as specified in the protocol.”In the company’s words, NCT06976190 on ClinicalTrials.gov
Tested for
Recurrent or Metastatic Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma
Main trialPhase 3
“This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.”In the company’s words, NCT06976190 on ClinicalTrials.gov

Other drugs for Recurrent or Metastatic Nasopharyngeal Carcinoma

All 266 drugs for Recurrent or Metastatic Nasopharyngeal Carcinoma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Recruiting May 2029 A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 2Recruiting Dec 2027 Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
Phase 1/2Recruiting Apr 2028 MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Phase 2Authorised not given Randomized Phase 2 trial of induction treatment of anti-PD-1 pucotenlimab and EGFR-ADC MRG003 or EGFR-ADC alone followed by chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (LA-SCCHN).
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pucotenlimab

Following is part of Solo: you see every change to Pucotenlimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in